Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study
Overview
- Phase
- Phase 2
- Intervention
- Toripalimab
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Sponsor
- Ruijin Hospital
- Enrollment
- 29
- Locations
- 2
- Primary Endpoint
- Major Pathological Response (MPR)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The study is a prospective, open label, multicenter, single arm Phase II clinical trial, aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for further improving the prognosis of NSCLC patients. This study will provide valuable information for further clinical trials of neoadjuvant Toripalimab and other immune checkpoint inhibitors in NSCLC patients with EGFR mutations and PD-L1 positive expression.
Detailed Description
For resectable locally advanced non-small cell lung cancer (NSCLC), the combination of neoadjuvant therapy and surgery has benefited the patients and has become a clinical routine and guideline recommended treatment. Among the East Asian NSCLC population, about 30% are positive for EGFR driver gene mutations. The efficacy of this population receiving neoadjuvant chemotherapy and EGFR inhibitors is limited, and their optimal neoadjuvant treatment strategy is still unclear. The neoadjuvant immunotherapy has achieved good therapeutic effects in driver-negative NSCLC patients, and is superior in PD-L1 expression positive patients. Based on the above evidence, the investigators plan to conduct a prospective, open label, multicenter, single arm Phase II clinical study to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for further improving the prognosis of NSCLC patients.
Investigators
Hecheng Li M.D., Ph.D
Chair of thoracic department
Ruijin Hospital
Eligibility Criteria
Inclusion Criteria
- •Men and women aged ≥ 18 years old.
- •Baseline tumor tissues have to be obtained through biopsy (percutaneous or transbronchial) or surgery at study center.
- •Histologically confirmed diagnosis of primary non-small lung cancer on non-squamous histology.
- •Pre-treatment stage as clinical II-IIIB (AJCC/UICC 8th Edition) (stage IIIB excludes N3 disease); curative resectability has to be explicitly verified by the experienced surgical investigator.
- •Confirmation by the central laboratory that the tumor harbors EGFR mutations either sensitive mutations, uncommon mutations or complex mutations.
- •Have a PD-L1 tumor proportion score (TPS) ≥ 1% determined by IHC at the central laboratory. In order to balance patients with high PD-L1 expression (≥50%) and low PD-L1 expression (1-49%), we planned to enroll PD-L1 high and low patients at a ratio of 1:
- •Have not received prior systemic treatment for NSCLC.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Expected survival ≥ 3 months.
- •Adequate blood and organ function.
Exclusion Criteria
- •Patients with histologically confirmed squamous cell carcinoma, combined small cell carcinoma and large cell carcinoma.
- •Molecular testing confirmed ALK translocation.
- •Treatment with prior systemic cancer therapy for the current lung cancer at any time (chemotherapy, radiotherapy, target therapy, ablation, and any other local or systemic therapy).
- •Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colorectal, endometrial, cervical, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
- •Any active or history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. Subjects with vitiligo, type I diabetes mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included.
- •Subjects with a history of interstitial lung disease, pneumonitis, or poorly controlled lung disease (including pulmonary fibrosis, acute lung diseases).
- •Severe chronic or active infections that require systemic antimicrobial, antifungal, or antiviral treatment, including tuberculosis infections.
- •Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA ≥ 500 IU/mL \[2500 copies/mL\] should be excluded.
- •Has known active hepatitis C virus (HCV). Active HCV is defined by positive tests for HCV Ab and quantitative HCV RNA.
- •Known positive history or positive test for Human Immunodeficiency Virus (HIV).
Arms & Interventions
Toripalimab
Neoadjuvant Toripalimab 240 mg IV on cycle 1 day 1 (C1D1), C2D1 and C3D1 before radical surgery for lung cancer. The participants will attend follow-up visits based on molecular residual disease (MRD) and receive adjuvant treatment including EGFR-TKI or chemotherapy if recommended.
Intervention: Toripalimab
Outcomes
Primary Outcomes
Major Pathological Response (MPR)
Time Frame: MPR will be assessed within 2 weeks after surgery
Defined as the incidence rate in postoperative pathology where the percentage of surviving tumor cells in the tumor bed is ≤ 10%, regardless of the presence or absence of live tumor cells in the lymph nodes.
Secondary Outcomes
- Pathological Complete Response (pCR)(pCR will be assessed within 2 weeks after surgery)
- Objective Response Rate (ORR)(Tumor response will be evaluated within 30 days after last dose of neoadjuvant treatment)
- 2-year Event Free Survival (EFS)(2 years after the date of initiation of neoadjuvant treatment)
- 2-year Overall Survival (OS)(2 years after the date of initiation of neoadjuvant treatment)
- Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events)(From date of neoadjuvant treatment until surgery was applied during study period or up to at least 90 days after last dose.)
- Feasibility (Number of Participants Who Finished Neoadjuvant therapy and Receive Surgery Within 3-6 Weeks After Neoadjuvant Therapies)(6 weeks after last dose of neoadjuvant treatment)